257 related articles for article (PubMed ID: 11950252)
21. Efficacy and safety of naproxcinod in the treatment of patients with osteoarthritis of the knee: a 13-week prospective, randomized, multicenter study.
Schnitzer TJ; Kivitz A; Frayssinet H; Duquesroix B
Osteoarthritis Cartilage; 2010 May; 18(5):629-39. PubMed ID: 20202489
[TBL] [Abstract][Full Text] [Related]
22. A comparison of the upper gastrointestinal mucosal effects of valdecoxib, naproxen and placebo in healthy elderly subjects.
Goldstein JL; Kivitz AJ; Verburg KM; Recker DP; Palmer RC; Kent JD
Aliment Pharmacol Ther; 2003 Jul; 18(1):125-32. PubMed ID: 12848634
[TBL] [Abstract][Full Text] [Related]
23. Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib.
Tannenbaum H; Berenbaum F; Reginster JY; Zacher J; Robinson J; Poor G; Bliddal H; Uebelhart D; Adami S; Navarro F; Lee A; Moore A; Gimona A
Ann Rheum Dis; 2004 Nov; 63(11):1419-26. PubMed ID: 15020310
[TBL] [Abstract][Full Text] [Related]
24. A single preoperative oral dose of valdecoxib, a new cyclooxygenase-2 specific inhibitor, relieves post-oral surgery or bunionectomy pain.
Desjardins PJ; Shu VS; Recker DP; Verburg KM; Woolf CJ
Anesthesiology; 2002 Sep; 97(3):565-73. PubMed ID: 12218521
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and tolerability of lumiracoxib in the treatment of osteoarthritis of the knee: a 13-week, randomized, double-blind comparison with celecoxib and placebo.
Sheldon E; Beaulieu A; Paster Z; Dutta D; Yu S; Sloan VS
Clin Ther; 2005 Jan; 27(1):64-77. PubMed ID: 15763607
[TBL] [Abstract][Full Text] [Related]
26. Antiinflammatory and analgesic efficacy of COX-2 specific inhibition: from investigational trials to clinical experience.
Bensen WG
J Rheumatol Suppl; 2000 Oct; 60():17-24. PubMed ID: 11032098
[TBL] [Abstract][Full Text] [Related]
27. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis.
Lohmander LS; McKeith D; Svensson O; Malmenäs M; Bolin L; Kalla A; Genti G; Szechinski J; Ramos-Remus C;
Ann Rheum Dis; 2005 Mar; 64(3):449-56. PubMed ID: 15345500
[TBL] [Abstract][Full Text] [Related]
28. A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.
Matsumoto AK; Melian A; Mandel DR; McIlwain HH; Borenstein D; Zhao PL; Lines CR; Gertz BJ; Curtis S;
J Rheumatol; 2002 Aug; 29(8):1623-30. PubMed ID: 12180720
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.
Leung AT; Malmstrom K; Gallacher AE; Sarembock B; Poor G; Beaulieu A; Castro R; Sanchez M; Detora LM; Ng J
Curr Med Res Opin; 2002; 18(2):49-58. PubMed ID: 12017209
[TBL] [Abstract][Full Text] [Related]
30. Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis.
Goldstein JL; Correa P; Zhao WW; Burr AM; Hubbard RC; Verburg KM; Geis GS
Am J Gastroenterol; 2001 Apr; 96(4):1019-27. PubMed ID: 11316141
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.
Ott E; Nussmeier NA; Duke PC; Feneck RO; Alston RP; Snabes MC; Hubbard RC; Hsu PH; Saidman LJ; Mangano DT; ;
J Thorac Cardiovasc Surg; 2003 Jun; 125(6):1481-92. PubMed ID: 12830070
[TBL] [Abstract][Full Text] [Related]
32. A randomized, double-blind, crossover comparative endoscopy study on the gastroduodenal tolerability of a highly specific cyclooxygenase-2 inhibitor, flosulide, and naproxen.
Bjarnason I; Macpherson A; Rotman H; Schupp J; Hayllar J
Scand J Gastroenterol; 1997 Feb; 32(2):126-30. PubMed ID: 9051872
[TBL] [Abstract][Full Text] [Related]
33. Gastroduodenal tolerability of highly specific cyclo-oxygenase-2 inhibitor.
Hayllar J; Bjarnason I
Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():30-2. PubMed ID: 9032580
[TBL] [Abstract][Full Text] [Related]
34. Review article: The pharmacological properties and clinical use of valdecoxib, a new cyclo-oxygenase-2-selective inhibitor.
Alsalameh S; Burian M; Mahr G; Woodcock BG; Geisslinger G
Aliment Pharmacol Ther; 2003 Feb; 17(4):489-501. PubMed ID: 12622757
[TBL] [Abstract][Full Text] [Related]
35. Effective treatment of laparoscopic cholecystectomy pain with intravenous followed by oral COX-2 specific inhibitor.
Joshi GP; Viscusi ER; Gan TJ; Minkowitz H; Cippolle M; Schuller R; Cheung RY; Fort JG
Anesth Analg; 2004 Feb; 98(2):336-342. PubMed ID: 14742366
[TBL] [Abstract][Full Text] [Related]
36. Valdecoxib: a review of its use in the management of osteoarthritis, rheumatoid arthritis, dysmenorrhoea and acute pain.
Fenton C; Keating GM; Wagstaff AJ
Drugs; 2004; 64(11):1231-61. PubMed ID: 15161329
[TBL] [Abstract][Full Text] [Related]
37. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
Geis GS
Scand J Rheumatol Suppl; 1999; 109():31-7. PubMed ID: 10422544
[TBL] [Abstract][Full Text] [Related]
38. Valdecoxib.
Baker DE
Rev Gastroenterol Disord; 2002; 2(3):116-25. PubMed ID: 12227215
[TBL] [Abstract][Full Text] [Related]
39. Celecoxib in the treatment of primary dysmenorrhea: results from two randomized, double-blind, active- and placebo-controlled, crossover studies.
Daniels S; Robbins J; West CR; Nemeth MA
Clin Ther; 2009 Jun; 31(6):1192-208. PubMed ID: 19695387
[TBL] [Abstract][Full Text] [Related]
40. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
